The protective effect of zoledronic acid on bone loss in postmenopausal women with early breast cancer treated with sequential tamoxifen and letrozole: 36-month follow-up. Academic Article uri icon


  • e11111 Background: Adjuvant treatment with aromatase inhibitors (AIs) in postmenopausal women (PMW) with early breast cancer (EBC) can be associated with bone loss. Update of BIG-98 suggests that sequential TAM and Letrozole (LET) have similar efficacy to 5 years of LET. This study evaluates whether addition of zoledronic acid (ZOL) to LET, switched from TAM, can prevent bone loss. Methods: This is an open-label, randomized phase II study of PMW with hormone receptor positive EBC previously treated with TAM for 2.5 years, with bone mineral density (BMD) T-score ≥ -2.5. Patients were randomly assigned to receive 2.5mg/day LET +/- ZOL. Patients on treatment arm receive 5 intravenous administrations of 4 mg ZOL every 6 months. All patients are evaluated with blood chemistry and BMD test every 6 months in the first 3 years and yearly in the next 2 years. All patients receive vitamin D and calcium supplements. A comparison between groups and between time points was performed by one-way ANOVA with repeated meas...

publication date

  • January 1, 2011